Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer

British Journal of Cancer

Volumn 86, Issue 5, 2002, Pages 686-691

  Parker, C C ^a   Norman, A R ^a   Huddart, R A ^a   Horwich, A ^a   Dearnaley, D P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Neoadjuvant androgen deprivation; Prognostic factors; Prostate cancer; PSA control; Radiotherapy

Indexed keywords

CYPROTERONE ACETATE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; CYPROTERONE ACETATE; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PATIENT CARE PLANNING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0037017861     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600160     Document Type: Article

References (36)

1. Consensus statement: Guidelines for PSA following radiation therapy
2. Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV
3. Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localised prostate cancer
4. Phase III Trial of dose escalation using conformal radiotherapy in prostate cancer: Side effects and PSA control
5. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial
6. Rationale and initial results of adjuvant hormone therapy and irradiation for prostate cancer
7. Dilemmas in treating early prostate cancer: The evidence and a questionnaire survey of consultant urologists in the United Kingdom
8. Neoadjuvant hormonal downsizing of localised carcinoma of the prostate: Effects on the volume of normal tissue irradiation
9. Prostate specific antigen after radiotherapy for prostate cancer: A re-evaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University
10. RTOG Protocol 92-02: A phase III trial of the use of long term androgen suppression following neoadjuvant cytoreduction and radiotherapy in locally advanced carcinoma of the prostate
11. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation
12. Non-parametric estimation from incomplete observations
13. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
14. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer
15. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level = < 10ng/ml: Radiation therapy or surgery?
16. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer
17. A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution
18. The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment
19. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonistadministered in the neoadjuvant setting: Implications for dosing schedule and neoadjuvant study consideration
20. Salvage radiotherapy for PSA failure after radical prostatectomy
21. Asymptotically efficient invariant procedures
22. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate
23. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group
24. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer
25. A phase III randomized trial to evaluate the efficacy of neoadjuvant therapy prior to curative radiotherapy in locally advanced prostate cancer patients
26. A catalog of prostate cancer nomograms
27. British urological surgery practice: 1. Prostate cancer
28. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate
29. Radiotherapy options for localised prostate cancer based upon pretreatment serum PSA levels and biochemical control: A comprehensive review of the literature
30. The potential for normal tissue dose reduction with neo-adjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer
31. Predictors of improved outcome for patients with localized prostate cancer treatment with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy
32. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy
33. The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome
34. Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: New insights into outcome from repeat biopsy and prostate specific antigen followup
35. Androgen deprivation and radiation therapy: Sequencing studies using the Shionogi in vivo tumor system